October 18, 2016 / 12:36 PM / 9 months ago

BRIEF-Atara Bio granted access to priority medicines

1 Min Read

Oct 18 (Reuters) - Atara Biotherapeutics Inc :

* Atara bio granted access to priority medicines (prime) regulatory support for allogeneic epstein-barr virus (ebv)-specific cytotoxic T lymphocytes (ctl) for treatment of ebv-associated post transplant lymphoproliferative disorder (ebv-ptld)

* Atara biotherapeutics - anticipates initiation of 2 phase 3 trials in RituxiMab refractory EBV-PTLD after HCT or solid organ transplantlater this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below